Table 1 Characteristics of the studies included in meta-analysis of association between hypertension status and prostate cancer risk.
From: Hypertension and risk of prostate cancer: a systematic review and meta-analysis
Study | Year | Region | Study design | No. of cases | Age (yr) | Exposure assessment | Outcome assessment | Matched or adjusted factors | NOS score |
|---|---|---|---|---|---|---|---|---|---|
Su et al. | 2015 | Taiwan | Nested case-control | 74 | 54.87 (SD 18.69) | Database | Database | Age, sex, residence and insurance premium | 7 |
Bhindi et al. | 2015 | Canada | Cohort | 2,235 | 64.9 | Measurement | Biopsy | Age, ethnicity, family history of prostate cancer, prostate volume, history of any prior biopsy and 5a-reductase inhibitor use | 8 |
Pai et al. | 2015 | Taiwan | Cohort | 1,971 | 69.31 (SD 9.31) | Database | Database | Age, income, urbanization level and index day | 7 |
Romero et al. | 2012 | Brazil | Cohort | 58 | ≥40 | Measurement | Biopsy | Age | 5 |
Ganesh et al. | 2011 | India | Case-control | 123 | 64 | Questionnaire | Histologically proven | Age, religion and education | 4 |
Pelucchi et al. | 2011 | Italy | Case-control | 1,294 | 66 (46–74) | Self-reported | Histologically confirmed | Age, study center, education, smoking, alcohol, physical activity, family history of prostate cancer and nonalcoholic energy intake | 7 |
Wallner et al. | 2011 | US | Cohort | 206 | 40–79 | Physician-diagnosed | Biopsy | Age | 6 |
Grundmark et al. | 2010 | Sweden | Cohort | 237 | NA | Measurement | Database | NA | 5 |
Martin et al. | 2010 | Norway | Cohort | 1,974 | 50.3 (SD 15.2) | Physical examination | Cancer registry | Age, height, BMI, smoking, marital status, education, physical activity, diabetes and country of origin | 8 |
Stocks et al. | 2010 | Sweden | Cohort | 10,002 | 70.1 (SD 8.4) | Health examination | Cancer registry | Age, smoking and BMI | 7 |
Beebe-Dimmer et al. | 2009 | US | Case-control | 637 | 62 | Medical records | Database | Age, PSA screening, diabetes, BMI, HDL and triglycerides | 6 |
Inoue et al. | 2009 | Japan | Cohort | 86 | 40–69 | Measurement | Cancer registry | Age, study area, smoking, ethanol intake and serum cholesterol | 7 |
Beebe-Dimmer et al. | 2007 | US | Case-control | 139 | 40–79 | Questionnaire | Cancer registry | Age and smoking history | 7 |
Tuohimaa et al. | 2007 | Finland | Nested case-control | 132 | 62.1 (SD 4.9) | Measurement | Cancer registry | Vitamin D | 5 |
Lund Håheim et al. | 2006 | Norway | Cohort | 507 | 40–49 | Questionnaire | Cancer registry | Age | 5 |
Tande et al. | 2006 | US | Cohort | 385 | 45–64 | Clinical examination | Cancer registry | Age, race, family history, education, smoking, ethanol intake, caloric intake and milk intake | 6 |
Ronquist et al. | 2004 | UK | Nested case-control | 1,013 | 50–79 | Database | Medical record | Age, smoking, BMI, alcohol, diabetes, IHD, HF, prostatism and calendar year | 6 |
Fitzpatrick et al. | 2001 | US | Cohort | 209 | ≥65 | Clinical examination | Medical record | Age, race and BMI | 6 |
Rosengren et al. | 1998 | Sweden | Cohort | 263 | 47–55 | Screening examination | Cancer registry | Age | 5 |
Friedman et al. | 1997 | US | Cohort | 2,297 | 30–79 | Health checkup | Cancer registry | Age, race, BMI and alcohol consumption | 7 |
Tulinius et al. | 1997 | Iceland | Cohort | 524 | 50.3 (SD 11) | Questionnaire | Cancer registry | Age | 5 |
